US equities |
MU $878.84 ▼-5.63% NVDA $214.13 ▼-1.43% TSLA $354.72 ▼-2.13% AAPL $343.46 ▲+0.43% META $709.33 ▼-3.72% MSFT $529.05 ▼-1.93% SPCX $146.03 ▼-1.74% AMD $528.75 ▼-5.95%
FinancialContent

Kronos Bio, Inc. - Common Stock (NQ:KRON)

0.8800 UNCHANGED
Last Price Updated: 9:38 AM EDT, Jun 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.8800
Bid (Size) 0.8729 (15)
Ask (Size) 0.8800 (31)
Prev. Close 0.8800
Today's Range 0.8800 - 0.8800
52wk Range 0.8800 - 0.8800
Shares Outstanding 56,769,091
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Which stocks are gapping on Thursday? ↗
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Thursday. Let's explore the market movements and identify the stocks with significant gaps. 
Via Chartmill

Performance

More News

Read More
News headline image
These stocks are moving in today's pre-market session ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
Via Benzinga
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AXL, KRON, PRA, SWTX on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, XAGE, SSBK on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Longevity Health Holdings, Inc. (Nasdaq - XAGE), Southern States Bancshares, Inc. (Nasdaq
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
In today's session, these stocks are experiencing unusual volume. ↗
Via Chartmill
News headline image
KRONOS BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Kronos Bio, Inc. - KRON
From Kahn Swick & Foti, LLC
Via Business Wire
News headline image
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DNB, COLB, KRON on Behalf of Shareholders
From Halper Sadeh LLC
Via GlobeNewswire
News headline image
Here are the top movers in Thursday's session. ↗
Via Chartmill
News headline image
Top stock movements in today's session. ↗
Via Chartmill
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
Via Benzinga
News headline image
The market is filled with gapping stocks in Thursday's session. ↗
Via Chartmill
News headline image
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Kronos Bio, Inc. (Nasdaq - KRON), Regulus Therapeutics Inc. (Nasdaq – RGLS), Coeptis Therapeutics Holdings, Inc. (Nasdaq – COEP), Pacific Premier Bancorp, Inc.
From Brodsky & Smith LLC
Via GlobeNewswire
News headline image
Shareholder Alert: The Ademi Firm Investigates Whether Kronos Bio, Inc. is Obtaining a Fair Price for Its Public Shareholders
From Ademi & Fruchter LLP
Via Business Wire
News headline image
KRON Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Kronos Bio, Inc. Is Fair to Shareholders
From Halper Sadeh LLC
Via Business Wire
News headline image
Kronos Bio Enters into Agreement to Be Acquired by Concentra Biosciences for $0.57 in Cash per Share Plus a Contingent Value Right
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Reports Fourth Quarter and Full Year 2024 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Shakes Up Leadership - Cuts 83% Of Workforce Amid Strategic Overhaul ↗
Via Benzinga
News headline image
Kronos Bio Announces CEO Transition and Reduction in Force
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Deal Dispatch: Starbucks Considers China Sale, Private Equity Bankrupts Snack Company, Darwin Financial Talks Mining ↗
Via Benzinga
News headline image
Deal Dispatch: Shell, Unilever And More Are On The Sell Side; The Onion Makes Alex Jones Cry Foul ↗
Via Benzinga
News headline image
Kronos Bio Highlights Preclinical Data that Show p300 KAT Inhibitors Reduce Inflammation in an Oral Presentation at ACR Convergence 2024
From Kronos Bio, Inc.
Via GlobeNewswire
News headline image
Kronos Bio Reports Third Quarter 2024 Financial Results and Corporate Update Including Plan to Evaluate Strategic Alternatives
From Kronos Bio, Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Kronos Bio, Inc. - Common Stock publicly traded?
Yes, Kronos Bio, Inc. - Common Stock is publicly traded.
What exchange does Kronos Bio, Inc. - Common Stock trade on?
Kronos Bio, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Kronos Bio, Inc. - Common Stock?
The ticker symbol for Kronos Bio, Inc. - Common Stock is KRON on the Nasdaq Stock Market
What is the current price of Kronos Bio, Inc. - Common Stock?
The current price of Kronos Bio, Inc. - Common Stock is 0.8800
When was Kronos Bio, Inc. - Common Stock last traded?
The last trade of Kronos Bio, Inc. - Common Stock was at 06/20/25 09:38 AM ET
What is the market capitalization of Kronos Bio, Inc. - Common Stock?
The market capitalization of Kronos Bio, Inc. - Common Stock is 49.96M
How many shares of Kronos Bio, Inc. - Common Stock are outstanding?
Kronos Bio, Inc. - Common Stock has 50M shares outstanding.